You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Regulatory impact statement (RIS) - update to the Required Advisory Statements for Medicine Labels (RASML)
The Regulatory Impact Statement (RIS) prepared by the TGA in May 2013 documents the proposal to update the Required Advisory Statements for Medicine Labels (the RASML) to:
- Include new and amended mandatory advisory statements.
- Implement the RASML document as a Legislative Instrument.